PATENT CLAIM ANALYSIS

Application Number: 15780046
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-08
Patent Classification: ["424", "133100"]

Abstract:
A novel antibody against VEGFR2 for use in the prevention or treatment of macular degeneration and cancer, which are angiogenesis-related diseases. The antibody of the present invention is an antibody which specifically binds to VEGFR2 which is overexpressed in vascular endothelial cells. The antibody of the present invention has very low homology compared to the CDR sequences of conventional VEGFR2 target antibodies, and thus is unique in its sequence. Since the antibody of the present invention, when treated alone, has the ability to inhibit vascular endothelial cell growth equivalent to that of ramucirumab which is conventionally used, it is very effective to prevent or treat angiogenesis-related diseases.

Claim (Index 17):
A pharmaceutical composition for preventing or treating an angiogenesis-related disease, the pharmaceutical composition comprising: (a) a pharmaceutically effective amount of the antibody against VEGFR2 or antigen binding fragment thereof of  claim 14 ; and (b) a pharmaceutically acceptable carrier.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 93.0
- Lexical Diversity: 1.75758
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15563950', '13768005', '12267515', '15517778', '13225792']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7242632377072645
- 35 USC 102 Novelty (BERT): 0.5411561830754351
- Combined Prediction Score: 0.7059525322440816
- Mean Citation Score: 346.214826
- Max Citation Score: 376.01364
- Similarity Product: 327.90141249960425

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test